$FunPep (4881.JP)$On the fifth day, it announced that it has signed a contract with Osaka University concerning the shared patent for antibody-induced peptide FPP004X, which allows for the company's exclusive research and development, production, and sales, as well as the implementation license to third parties around the world based on the effectiveness of its patent rights.
Antibody-induced peptide FPP004X is a peptide that induces antibodies against the target protein IgE, which is expected to have a sustained effect on allergies by causing immune cells to produce anti-IgE antibodies for a certain period of time.
The company aims to provide a new and convenient treatment option for patients by alleviating symptoms throughout the season by administering prior to pollen dispersal. The company has signed an option contract with Shionogi for exclusive rights to research and development, production, and sales of FPP004X worldwide. Under the collaboration with Shionogi, the company is promoting the research and development of FPP004X, which is currently undergoing preclinical trials, with the aim of starting clinical trials in Japan in 2025.
With the implementation of this contract, the company plans to pay Osaka University a contract lump sum payment. Furthermore, it plans to pay some of the lump sum payments, milestones, and royalties received from Shionogi regarding the option contract.